Search

Author/Creator Kaufman, David R

1. A Phase I/III, multicenter, open-label trial of talimogene laherparepvec (T-VEC) in combination with pembrolizumab for the treatment of unresected, stage IIIb-IV melanoma (MASTERKEY-265). (4th November 2015)

Authors:
Long, Georgina V; Dummer, Reinhard; Ribas, Antoni; Puzanov, Igor; Michielin, Olivier; VanderWalde, Ari; Andtbacka, Robert HI; Cebon, Jonathan; Fernandez, Eugenio; Malvehy, Josep; Olszanski, Anthony J; Gajewski, Thomas F; Kirkwood, John M; Kuznetsova, Olga; Chen, Lisa; Kaufman, David R; Chou, Jeff...
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Preliminary results from a Phase I/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. (4th November 2015)

Authors:
Gangadhar, Tara C; Hamid, Omid; Smith, David C; Bauer, Todd M; Wasser, Jeffrey S; Luke, Jason J; Balmanoukian, Ani S; Kaufman, David R; Zhao, Yufan; Maleski, Janet; Leopold, Lance; Gajewski, Thomas F
Journal:
Journal for immunotherapy of cancer
Issue:
Volume 3(2015)Supplement 2
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search